Demansta Nükleer Tıp Görüntülemelerinde Yenilikler

AKDEMİR, Ümit; Saka Topçuoğlu, Esen; Atay, Lütfiye Özlem

doi:10.29399/npa.28155

Demansta Nükleer Tıp Görüntülemelerinde Yenilikler

Esen SAKA, (Hacettepe Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Ankara, Türkiye)

Ümit AKDEMİR, (Gazi Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Ankara, Türkiye)

Lütfiye ATAY (Gazi Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Ankara, Türkiye)

Nöropsikiyatri Arşivi

15 2

Yıl: 2022 Cilt: 59 Sayı: Ek 1 Sayfa Aralığı: 17 - 23 Metin Dili: Türkçe DOI: 10.29399/npa.28155 İndeks Tarihi: 05-05-2023

Demansta Nükleer Tıp Görüntülemelerinde Yenilikler

Öz:

Alzheimer hastalığı (AH) ve diğer dejeneratif demansların moleküler biyolojisi, patolojisi ve genetiği ile ilgili gelişmeler, bu hastalıklara özgü biyobelirteçlerin ve nükleer tıp alanında radyo-işaretleyicilerin gelişmesini sağlamıştır. Görüntüleme ve görüntüleme dışı belirteçler bu hastalıkların çok erken tanınmalarını sağlayarak tanımlanmalarında da önemli değişikliklere neden olmuşlardır. Moleküler görüntüleme yöntemlerinden olan amiloid pozitron emisyon tomografisi (PET) ve tau PET, beyindeki glukoz metabolizma paternini gösteren florodeoksiglukoz (FDG) PET, dopaminerjik terminalleri işaretleyen dopamin taşıyıcı tek foton emisyon tomografisi (SPECT), AH’nı ve atipik varyantlarını, frontotemporal demansları ve Lewy cisimcikli demansı erken tanıma ve birbirlerinden ayırt etmede değerli araçlardır. Birbirlerine göre farklı üstünlükleri olan bu görüntüleme yöntemlerinin kullanım endikasyonları farklıdır ve kimi zaman birbirlerini tamamlayan bilgi verirler. Ayrıca, nöroenflamasyonu, astrositleri, sinaptik yoğunluğu ve kolinerjik terminalleri hedefleyen radyoişaretleyiciler ile araştırmalar devam etmektedir. Bu derlemede, AH ve diğer nörodejeneratif demanslarda rutin olarak kullanılan ya da yeni geliştirilen nükleer görüntüleme yöntemleri, kullanılan ajanlar ve tanısal özellikleri, olgu örnekleri ile beraber sunulacaktır.

Anahtar Kelime:

What is New in Nuclear Medicine Imaging for Dementia

Öz:

Advances in the molecular biology, pathology and genetics of Alzheimer’s disease (AD) and other degenerative dementias have led to the development of biomarkers specific to these diseases and radiotracers that are used in nuclear medicine. Imaging and nonimaging markers have enabled very early recognition of these diseases and have caused significant changes in their definitions. Amyloid positron emission tomography (PET) and tau PET, which are molecular imaging methods, [F18]fluorodeoxyglucose (FDG) PET showing the glucose metabolism pattern in the brain, dopamine transporter single photon emission computerized tomography (SPECT) that marks dopaminergic terminals are valuable tools for early recognition and differentiation of AD and its atypical variants, frontotemporal dementias and dementia with Lewy bodies. These imaging methods, which have different advantages over each other, have different indications for use and provide complementary information. In addition, research on radiotracers targeting neuroinflammation, astrocytes, synaptic density, and cholinergic terminals is ongoing. In this review, routinely used and newly developed nuclear imaging methods in AD and other neurodegenerative dementias, the agents used and their diagnostic features will be presented together with case examples.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Patel KP, Wymer DT, Bhatia VK, Duara R, Rajadhyaksha CD. Multimodality imaging of dementia: clinical importance and role of integrated anatomic and molecular imaging. Radiographics. 2020;40(1):200–222.
2. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. Embo Mol Med. 2016;8(6):595–608.
3. Knopman DS, Amieva H, Petersen RC, Chetelat G, Holtzman DM, Hyman BT ve ark. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33.
4. Chetelat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S ve ark. AmyloidPET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol. 2020;19(11):951–962.
5. Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB ve ark. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–547.
6. Dubois B, Feldman HH, Jacova C, Harald Hampel, José Luis Molinuevo, Kaj Blennow ve ark. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–629.
7. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH ve ark. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269.
8. Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225–236.
9. Klunk WE, Engler H, Nordberg A, Wang YM, Blomqvist G, Holt DP ve ark. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319.
10. van Waarde A, Marcolini S, de Deyn PP, Dierckx RA. PET agents in dementia: an overview. Semin Nucl Med. 2021;51(3):196–229.
11. Catafau AM, Bullich S. Amyloid PET imaging: applications beyond Alzheimer’s disease. Clin Transl Imaging. 2015;3(1):39–55.
12. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Jr MD, Jagust WJ ve ark. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1–15.
13. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR ve ark. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis. Jama-J Am Med Assoc. 2015;313(19):1924–1938.
14. Villemagne VL, Barkhof F, Garibotto V, Landau SM, Nordberg A, van Berckel BN. Molecular imaging approaches in dementia. Radiology. 2021;298(3):517– 530.
15. Fantoni ER, Chalkidou A, O’Brien JT, Farrar G, Hammers A. A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer’s disease. J Alzheimers Dis. 2018;63(2):783–796.
16. Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L ve ark. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019;321(13):1286–1294.
17. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P ve ark. Appropriate use criteria for amyloid PET. A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9(1): E1–E16.
18. Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J ve ark. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 2018;136(6):821–853.
19. Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643–663.
20. Leuzy A, Chiotis K, Lemoine L, Gillberg P-G, Almkvist O, Rodriguez-Vieitez E ve ark. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24(8):1112–1134.
21. Beyer L, Brendel M. Imaging of tau pathology in neurodegenerative diseases: an update. Semin Nucl Med. 2021;51(3):253–263.
22. Fleisher AS, Pontecorvo MJ, Devous Sr MD, Lu M, Arora AK, Truocchio SP ve ark. Positron emission tomography imaging with [F-18] flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829–839.
23. Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M ve ark. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539–1550.
24. Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D ve ark. Tau Positron Emission Tomographic Imaging in Aging and Early Alzheimer Disease. Ann Neurol. 2016;79(1):110–119.
25. Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P ve ark. Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between beta-amyloid and tauopathy. JAMA Neurol. 2016;73(9):1070–1077.
26. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259.
27. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 2010;33(7):317– 325.
28. Pontecorvo MJ, Devous Sr MD, Navitsky M, Lu M, Salloway S, Schaerf FW ve ark. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140(3):748–763.
29. Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O ve ark. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a headto-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78(8):961–971.
30. Graff-Radford J, Yong KX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC ve ark. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 2021;20(3):222–234.
31. Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and metaanalysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis. 2011;26(4):627–645.
32. Laforce Jr R, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW ve ark. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer’s pathology. Neuroimage Clin. 2014;4:508–516.
33. Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE ve ark. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology. 2013;266(2):583–591.
34. Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R ve ark. Mild cognitive impairment with suspected nonamyloid pathology (SNAP) Prediction of progression. Neurology. 2015;84(5):508–515.
35. Blazhenets G, Ma YL, Sörensen A, Schiller F, Rücker G, Eidelberg D ve ark. Predictive value of 18F-florbetapir and 18F-FDG PET for conversion from mild cognitive impairment to Alzheimer dementia. J Nucl Med. 2020;61(4):597–603.
36. Cai Z, Li S, Matuskey D, Nabulsi N, Huang Y. PET imaging of synaptic density: a new tool for investigation of neuropsychiatric diseases. Neurosci Lett. 2019;691:44–50.
37. Yang S-K, Chen W, Su C-H, Liu C-H. Incidence and comorbidity of dementia with Lewy bodies: a population-based cohort study. Behav Neurol. 2018;2018:7631951.
38. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D ve ark. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.
39. Akdemir ÜÖ, Bora Tokçaer A, Atay LÖ. Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders. Turk J Med Sci. 2021;51(2):400–410.
40. Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL ve ark. 18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases. Brain. 2020;143(11):3477–3494.
41. Lyoo CH, Cho H, Choi JY, Ryu YH, Lee MS. Tau positron emission tomography imaging in degenerative Parkinsonisms. J Mov Disord. 2018;11(1):1–12.
42. Caminiti SP, Sala A, Iaccarino L, Beretta L, Pilotto A, Gianolli L ve ark. Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. Alzheimers Res Ther. 2019;11.
43. Minoshima S, Mosci K, Cross D, Thientunyakit T. Brain [F-18] FDG PET for clinical dementia workup: differential diagnosis of Alzheimer’s disease and other types of dementing disorders. Semin Nucl Med. 2021;51(3):230–240.
44. Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B ve ark. EANM procedure guidelines for brain PET imaging using [18F] FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49(2):632–651.

APA	Saka Topçuoğlu E, AKDEMİR Ü, Atay L (2022). Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. , 17 - 23. 10.29399/npa.28155
Chicago	Saka Topçuoğlu Esen,AKDEMİR Ümit,Atay Lütfiye Özlem Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. (2022): 17 - 23. 10.29399/npa.28155
MLA	Saka Topçuoğlu Esen,AKDEMİR Ümit,Atay Lütfiye Özlem Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. , 2022, ss.17 - 23. 10.29399/npa.28155
AMA	Saka Topçuoğlu E,AKDEMİR Ü,Atay L Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. . 2022; 17 - 23. 10.29399/npa.28155
Vancouver	Saka Topçuoğlu E,AKDEMİR Ü,Atay L Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. . 2022; 17 - 23. 10.29399/npa.28155
IEEE	Saka Topçuoğlu E,AKDEMİR Ü,Atay L "Demansta Nükleer Tıp Görüntülemelerinde Yenilikler." , ss.17 - 23, 2022. 10.29399/npa.28155
ISNAD	Saka Topçuoğlu, Esen vd. "Demansta Nükleer Tıp Görüntülemelerinde Yenilikler". (2022), 17-23. https://doi.org/10.29399/npa.28155

APA	Saka Topçuoğlu E, AKDEMİR Ü, Atay L (2022). Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. Nöropsikiyatri Arşivi, 59(Ek 1), 17 - 23. 10.29399/npa.28155
Chicago	Saka Topçuoğlu Esen,AKDEMİR Ümit,Atay Lütfiye Özlem Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. Nöropsikiyatri Arşivi 59, no.Ek 1 (2022): 17 - 23. 10.29399/npa.28155
MLA	Saka Topçuoğlu Esen,AKDEMİR Ümit,Atay Lütfiye Özlem Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. Nöropsikiyatri Arşivi, vol.59, no.Ek 1, 2022, ss.17 - 23. 10.29399/npa.28155
AMA	Saka Topçuoğlu E,AKDEMİR Ü,Atay L Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. Nöropsikiyatri Arşivi. 2022; 59(Ek 1): 17 - 23. 10.29399/npa.28155
Vancouver	Saka Topçuoğlu E,AKDEMİR Ü,Atay L Demansta Nükleer Tıp Görüntülemelerinde Yenilikler. Nöropsikiyatri Arşivi. 2022; 59(Ek 1): 17 - 23. 10.29399/npa.28155
IEEE	Saka Topçuoğlu E,AKDEMİR Ü,Atay L "Demansta Nükleer Tıp Görüntülemelerinde Yenilikler." Nöropsikiyatri Arşivi, 59, ss.17 - 23, 2022. 10.29399/npa.28155
ISNAD	Saka Topçuoğlu, Esen vd. "Demansta Nükleer Tıp Görüntülemelerinde Yenilikler". Nöropsikiyatri Arşivi 59/Ek 1 (2022), 17-23. https://doi.org/10.29399/npa.28155